KR20190110736A - 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 - Google Patents

신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 Download PDF

Info

Publication number
KR20190110736A
KR20190110736A KR1020180032548A KR20180032548A KR20190110736A KR 20190110736 A KR20190110736 A KR 20190110736A KR 1020180032548 A KR1020180032548 A KR 1020180032548A KR 20180032548 A KR20180032548 A KR 20180032548A KR 20190110736 A KR20190110736 A KR 20190110736A
Authority
KR
South Korea
Prior art keywords
triazol
aminomethyl
dihydro
hydrochloride
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020180032548A
Other languages
English (en)
Korean (ko)
Inventor
한태동
탁희재
김은경
최수빈
박솔
김동훈
김소영
최현호
김태왕
주미경
하나리
Original Assignee
주식회사유한양행
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사유한양행 filed Critical 주식회사유한양행
Priority to KR1020180032548A priority Critical patent/KR20190110736A/ko
Priority to JP2020550176A priority patent/JP7383627B2/ja
Priority to PCT/IB2019/052278 priority patent/WO2019180646A1/en
Priority to KR1020207029750A priority patent/KR102788118B1/ko
Priority to AU2019237344A priority patent/AU2019237344B2/en
Priority to CA3093057A priority patent/CA3093057A1/en
Priority to EP19772403.2A priority patent/EP3768675B1/en
Priority to US16/359,985 priority patent/US10995086B2/en
Priority to CN201980020696.5A priority patent/CN111886233B/zh
Priority to ARP190100713A priority patent/AR115007A1/es
Priority to TW108109864A priority patent/TWI803600B/zh
Publication of KR20190110736A publication Critical patent/KR20190110736A/ko
Priority to US17/208,887 priority patent/US11780830B2/en
Priority to JP2023128580A priority patent/JP2023145748A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020180032548A 2018-03-21 2018-03-21 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 Pending KR20190110736A (ko)

Priority Applications (13)

Application Number Priority Date Filing Date Title
KR1020180032548A KR20190110736A (ko) 2018-03-21 2018-03-21 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
US16/359,985 US10995086B2 (en) 2018-03-21 2019-03-20 Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same
CN201980020696.5A CN111886233B (zh) 2018-03-21 2019-03-20 三唑酮衍生物或其盐以及包含其的药物组合物
KR1020207029750A KR102788118B1 (ko) 2018-03-21 2019-03-20 신규한 트리아졸론 유도체 또는 그의 염, 및 그를 포함하는 제약 조성물
AU2019237344A AU2019237344B2 (en) 2018-03-21 2019-03-20 Novel triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same
CA3093057A CA3093057A1 (en) 2018-03-21 2019-03-20 Novel triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same
EP19772403.2A EP3768675B1 (en) 2018-03-21 2019-03-20 Novel triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same
JP2020550176A JP7383627B2 (ja) 2018-03-21 2019-03-20 新規トリアゾロン誘導体またはその塩、およびこれらを含む医薬組成物
PCT/IB2019/052278 WO2019180646A1 (en) 2018-03-21 2019-03-20 Novel triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same
ARP190100713A AR115007A1 (es) 2018-03-21 2019-03-21 Derivados de triazolona o sales de los mismos y composiciones farmacéuticas que comprenden los mismos
TW108109864A TWI803600B (zh) 2018-03-21 2019-03-21 新穎的三唑酮衍生物或其鹽及包含彼等之醫藥組合物
US17/208,887 US11780830B2 (en) 2018-03-21 2021-03-22 Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same
JP2023128580A JP2023145748A (ja) 2018-03-21 2023-08-07 新規トリアゾロン誘導体またはその塩、およびこれらを含む医薬組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020180032548A KR20190110736A (ko) 2018-03-21 2018-03-21 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물

Publications (1)

Publication Number Publication Date
KR20190110736A true KR20190110736A (ko) 2019-10-01

Family

ID=67986894

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020180032548A Pending KR20190110736A (ko) 2018-03-21 2018-03-21 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR1020207029750A Active KR102788118B1 (ko) 2018-03-21 2019-03-20 신규한 트리아졸론 유도체 또는 그의 염, 및 그를 포함하는 제약 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207029750A Active KR102788118B1 (ko) 2018-03-21 2019-03-20 신규한 트리아졸론 유도체 또는 그의 염, 및 그를 포함하는 제약 조성물

Country Status (10)

Country Link
US (2) US10995086B2 (cg-RX-API-DMAC7.html)
EP (1) EP3768675B1 (cg-RX-API-DMAC7.html)
JP (2) JP7383627B2 (cg-RX-API-DMAC7.html)
KR (2) KR20190110736A (cg-RX-API-DMAC7.html)
CN (1) CN111886233B (cg-RX-API-DMAC7.html)
AR (1) AR115007A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019237344B2 (cg-RX-API-DMAC7.html)
CA (1) CA3093057A1 (cg-RX-API-DMAC7.html)
TW (1) TWI803600B (cg-RX-API-DMAC7.html)
WO (1) WO2019180646A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022224195A1 (en) * 2021-04-22 2022-10-27 Yuhan Corporation Triazolones, tetrazolones, and imidazolones, or their salts, and pharmaceutical compositions comprising the same

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190110736A (ko) * 2018-03-21 2019-10-01 주식회사유한양행 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20190110740A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20200004036A (ko) * 2018-07-03 2020-01-13 주식회사유한양행 (e)-(2-(클로로메틸)-3-플루오로알릴)카바메이트 유도체의 제조방법
TWI835945B (zh) 2018-12-14 2024-03-21 南韓商柳韓洋行股份有限公司 3,3-二氟烯丙胺化物或其鹽及包含彼的醫藥組合物
TW202039486A (zh) 2018-12-14 2020-11-01 南韓商柳韓洋行股份有限公司 三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物
AU2020206477B2 (en) 2019-01-11 2022-11-10 Transthera Sciences (Nanjing), Inc. Haloallylamine compounds and application thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2725148A1 (de) 1977-06-03 1978-12-14 Hoechst Ag 1-aryl-4-alkyl-1,2,4-triazol-5-one und verfahren zu ihrer herstellung
US20050096360A1 (en) 2003-08-08 2005-05-05 Salter-Cid Luisa M. Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment of diseases
KR100572996B1 (ko) 2003-08-12 2006-04-25 한국화학연구원 불소화 비닐 에테르 측쇄기를 갖는 아졸계 살균제 화합물및 그의 제조방법
WO2005082343A2 (en) 2004-02-25 2005-09-09 La Jolla Pharmaceutical Company Amines and amides for the treatment of diseases
TW200726765A (en) 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
US20070293548A1 (en) 2006-03-31 2007-12-20 Wang Eric Y Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases
EP2139333A4 (en) * 2007-03-28 2010-11-10 Merck Sharp & Dohme SUBSTITUTED PYRID- [3,2-E] - [1,2,4] -TRIAZOL- [4,3-C] -PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS
MX2009009920A (es) * 2007-03-29 2009-10-19 Hoffmann La Roche Inhibidores no nucleosidos de transcriptasa inversa.
GB0722075D0 (en) * 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
US8426587B2 (en) 2007-11-21 2013-04-23 Pharmaxis Ltd. Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor
WO2010096722A1 (en) 2009-02-20 2010-08-26 Takeda Pharmaceutical Company Limited 3-oxo-2, 3-dihydro- [1,2, 4] triazolo [4, 3-a]pyridines as soluble epoxide hydrolase (seh) inhibitors
WO2013134562A1 (en) 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2871793C (en) 2012-05-02 2020-09-15 Pharmaxis Ltd. Substituted 3-haloallylamine inhibitors of ssao and uses thereof
CN105143210A (zh) * 2013-04-25 2015-12-09 柳韩洋行 新的三唑酮衍生物或其盐以及含有其的药物组合物
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2016092375A1 (en) * 2014-12-11 2016-06-16 Zenith Epigenetics Corp. Substituted heterocycles as bromodomain inhibitors
WO2016101119A1 (en) 2014-12-23 2016-06-30 Merck Sharp & Dohme Corp. Fused heteroaryl derivatives as orexin receptor antagonists
TW201722958A (zh) * 2015-09-15 2017-07-01 葛蘭素史克智慧財產(第二)有限公司 化學化合物
SG11201806700RA (en) 2016-02-12 2018-09-27 Pharmaxis Ltd Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof
EP3452469A1 (en) 2016-05-03 2019-03-13 Bayer Pharma Aktiengesellschaft Fluoroalkyl-substituted aryltriazole derivatives and uses thereof
WO2018027892A1 (en) 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
CA3041169A1 (en) 2016-10-19 2018-04-26 Boehringer Ingelheim International Gmbh Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
CN110709385A (zh) 2017-03-02 2020-01-17 法玛西斯有限公司 赖氨酰氧化酶的卤代烯丙胺吡唑衍生物抑制剂及其用途
WO2018196677A1 (zh) 2017-04-28 2018-11-01 四川科伦博泰生物医药股份有限公司 氟代烯丙胺衍生物及其用途
FI3626699T3 (fi) 2017-06-20 2023-08-15 Shandong Danhong Pharmaceutical Co Ltd Ssao:n estäjä
CN109810041B (zh) 2017-11-21 2023-08-15 药捷安康(南京)科技股份有限公司 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
CN109988109B (zh) 2017-12-29 2020-12-29 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其用途
KR20190110740A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20190110736A (ko) * 2018-03-21 2019-10-01 주식회사유한양행 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CN110938059A (zh) 2018-09-25 2020-03-31 上海轶诺药业有限公司 胺基脲敏感性胺氧化酶抑制剂制备及其应用
WO2020063854A1 (zh) 2018-09-27 2020-04-02 南京明德新药研发有限公司 作为vap-1抑制剂的喹啉类衍生物
EP3856176A4 (en) 2018-09-28 2022-05-04 Acucela Inc. INHIBITORS OF VAP-1
AU2019351124A1 (en) 2018-09-28 2021-05-20 Acucela Inc. Inhibitors of VAP-1
CN112789277B (zh) 2018-10-22 2022-11-04 广东东阳光药业有限公司 胍类衍生物及其用途
EP3870162A4 (en) 2018-10-24 2022-08-24 Metacrine, Inc. SSAO INHIBITORS AND USES THEREOF
TWI835945B (zh) 2018-12-14 2024-03-21 南韓商柳韓洋行股份有限公司 3,3-二氟烯丙胺化物或其鹽及包含彼的醫藥組合物
TW202039486A (zh) 2018-12-14 2020-11-01 南韓商柳韓洋行股份有限公司 三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物
AU2020206477B2 (en) 2019-01-11 2022-11-10 Transthera Sciences (Nanjing), Inc. Haloallylamine compounds and application thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022224195A1 (en) * 2021-04-22 2022-10-27 Yuhan Corporation Triazolones, tetrazolones, and imidazolones, or their salts, and pharmaceutical compositions comprising the same

Also Published As

Publication number Publication date
JP2021518384A (ja) 2021-08-02
JP7383627B2 (ja) 2023-11-20
EP3768675B1 (en) 2026-04-01
CA3093057A1 (en) 2019-09-26
EP3768675C0 (en) 2026-04-01
CN111886233A (zh) 2020-11-03
CN111886233B (zh) 2024-01-02
WO2019180646A1 (en) 2019-09-26
KR20200124759A (ko) 2020-11-03
TWI803600B (zh) 2023-06-01
US10995086B2 (en) 2021-05-04
US20210317110A1 (en) 2021-10-14
US11780830B2 (en) 2023-10-10
JP2023145748A (ja) 2023-10-11
EP3768675A4 (en) 2021-12-22
EP3768675A1 (en) 2021-01-27
US20190322655A1 (en) 2019-10-24
TW202003508A (zh) 2020-01-16
AR115007A1 (es) 2020-11-18
AU2019237344B2 (en) 2023-07-06
KR102788118B1 (ko) 2025-03-31
AU2019237344A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
CN111886233B (zh) 三唑酮衍生物或其盐以及包含其的药物组合物
AU2022288984B2 (en) 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same
KR20140075775A (ko) 과증식성 질환 치료시 Bub1 키나제 저해제로 사용하기 위한 치환된 벤질인다졸
JP7322052B2 (ja) 新規アリールもしくはヘテロアリールトリアゾロン誘導体もしくはそれらの塩、またはそれを含む医薬組成物
AU2019398820B2 (en) Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same
US20240109900A1 (en) Azabicyclic shp2 inhibitors
KR20200073499A (ko) 신규의 3,3-다이플루오로알릴아민 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20200073503A (ko) 트라이아졸로피리딘-3-온 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
HK40034427A (en) Novel triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20180321

PG1501 Laying open of application
PC1204 Withdrawal of earlier application forming a basis of a priority claim

Patent event date: 20180321

Comment text: Patent Application

Patent event code: PC12041R01I